Edition:
United Kingdom

argenx SE (ARGX.BR)

ARGX.BR on Brussels Stock Exchange

88.90EUR
11 Dec 2018
Change (% chg)

€0.90 (+1.02%)
Prev Close
€88.00
Open
€88.30
Day's High
€89.80
Day's Low
€87.90
Volume
102,263
Avg. Vol
123,677
52-wk High
€98.60
52-wk Low
€27.72

Chart for

About

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused... (more)

Overall

Beta: --
Market Cap(Mil.): €583.54
Shares Outstanding(Mil.): 26.89
Dividend: --
Yield (%): --

Financials

  ARGX.BR Industry Sector
P/E (TTM): -- 92.25 33.63
EPS (TTM): -1.07 -- --
ROI: -19.69 0.29 15.02
ROE: -19.69 0.94 16.60

AbbVie doubles down on cancer project with biotech group Argenx

BRUSSELS Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialize one of its experimental drugs which could lead to payments of up to $625 million.

22 Aug 2018

AbbVie doubles down on cancer project with biotech group Argenx

BRUSSELS Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialise one of its experimental drugs which could lead to payments of up to $625 million(490.08 million pounds).

22 Aug 2018

AbbVie doubles down on cancer project with biotech group Argenx

BRUSSELS, Aug 22 Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialise one of its experimental drugs which could lead to payments of up to $625 million.

22 Aug 2018

BRIEF-Argenx: Publication Of Study Results From Phase 1 Of FcRn-Antagonist Efgartigimod

* ANNOUNCED ON TUESDAY PUBLICATION OF FULL STUDY RESULTS FROM PHASE 1 OF FCRN-ANTAGONIST EFGARTIGIMOD (ARGX-113) IN HEALTHY VOLUNTEERS

25 Jul 2018

Earnings vs. Estimates